Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Short term Debt (2019 - 2022)

BioScience Health Innovations has reported Short term Debt over the past 4 years, most recently at $2893.0 for Q2 2022.

  • Quarterly Short term Debt fell 64.94% to $2893.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $2893.0 through May 2022, down 64.94% year-over-year, with the annual reading at $8713.0 for FY2021, 23.57% up from the prior year.
  • Short term Debt was $2893.0 for Q2 2022 at BioScience Health Innovations, down from $8713.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $8713.0 in Q3 2021 and troughed at $2893.0 in Q2 2022.
  • The 4-year median for Short term Debt is $7051.0 (2020), against an average of $6845.4.
  • Year-over-year, Short term Debt increased 28.9% in 2021 and then tumbled 64.94% in 2022.
  • A 4-year view of Short term Debt shows it stood at $6115.0 in 2019, then grew by 15.31% to $7051.0 in 2020, then rose by 23.57% to $8713.0 in 2021, then crashed by 66.8% to $2893.0 in 2022.
  • Per Business Quant, the three most recent readings for BHIC's Short term Debt are $2893.0 (Q2 2022), $8713.0 (Q4 2021), and $8713.0 (Q3 2021).